GSE114013
Identifying the molecular mode of action of itraconazole in colorectal cancer
Two cell lines (HT55 and SW948) were found responsive to itraconazole treatment.  To identify the mode of action cells were treated with itraconazole or control (DMSO) and then subjected to RNAseq analysis once the phenotype had developed Overall design: HT55 and SW948 cells were seeded in adherent culture and treated with 5uM itraconazole or DMSO for 6 days.  Cells then underwent RNA extraction using the RNAeasy Micro Plus kit (Qiagen) and quantified using the Qubit RNA Assay Kit (Thermo Fisher Scientific).  RNA quality was assessed using the Agilent Bioanalyser system as per manufacturer's instructions.  Following normalisation and sample randomisation, Truseq library (Illumina) preparation was carried out at the CRUK CI genomics facility and subsequent single end, 50bp sequencing using the HiSeq system (Illumina).  Following human genome alignment (hg19), read counts were normalised and differential expression tested using the DEseq protocol.